William Blair & Company’s Pacific Biosciences PACB Stock Holding History

William Blair & Company’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,079	Closed	-$349K	–	1972
2021 Q4	$349K	Buy	17,079 +3,970	+30%	+$95.8K	﹤0.01%	1365
2021 Q3	$335K	Buy	+13,109	New	+$388K	﹤0.01%	1303
2017 Q4	–	Sell	-27,811	Closed	-$146K	–	1427
2017 Q3	$146K	Hold	27,811	–	–	﹤0.01%	1285
2017 Q2	$99K	Sell	27,811 -49,300	-64%	-$199K	﹤0.01%	1424
2017 Q1	$389K	Hold	77,111	–	–	﹤0.01%	985
2016 Q4	$293K	Buy	+77,111	New	+$560K	﹤0.01%	1018
2016 Q3	–	Sell	-44,000	Closed	-$310K	–	1312
2016 Q2	$310K	Buy	+44,000	New	+$402K	﹤0.01%	966
2015 Q1	–	Sell	-21,000	Closed	-$164K	–	2184
2014 Q4	$164K	Hold	21,000	–	–	﹤0.01%	1981
2014 Q3	$103K	Buy	+21,000	New	+$110K	﹤0.01%	2025

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

William Blair & Company's PACB Position: Q1 2022 in Review

William Blair & Company sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 17,079 shares — an estimated $349K sold.

William Blair & Company first reported a position in PACB in Q3 2014 and held it in 9 quarters. The position peaked at $389K in Q1 2017. 249 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

William Blair & Company reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
William Blair & Company sold 17,079 Pacific Biosciences shares in Q1 2022, an estimated $349K.
William Blair & Company first reported a position in Pacific Biosciences in Q3 2014 and held it in 9 quarters.
William Blair & Company's Pacific Biosciences position peaked at $389K in Q1 2017.
249 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.